Dynavax Technologies Corporation Earnings Recaps
Q3 2025
Nov 6, 2025
Dynavax Technologies delivered robust third quarter results, highlighted by a 13% year-over-year increase in net product revenue for HEPLISAV-B and strategic advancement in its clinical pipeline, including an exclusive license for a novel oral COVID-19 vaccine candidate.
Key takeaways
- HEPLISAV-B generated $90 million in net revenue, achieving a 46% market share in the U.S. adult hepatitis B vaccine market.
- The company announced a new $100 million share repurchase program, reinforcing its commitment to shareholder value.
- Dynavax entered into a strategic partnership with Vaxart for a Phase IIb COVID-19 oral vaccine candidate, targeting a significant unmet need in COVID-19 prevention.
- Continued momentum in clinical pipeline advancement, with key developments in shingles and pandemic flu vaccine candidates underway.